{"id":"duration-of-treatment-z-phase-2-years","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Z-Phase works by modulating the immune system's response to inflammation, which is a key driver of various diseases. By reducing inflammation, Z-Phase aims to slow disease progression and alleviate symptoms. However, the exact molecular mechanisms underlying its effects are still being researched.","oneSentence":"Z-Phase is a medication that targets the body's natural processes to reduce inflammation and slow disease progression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:10.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe rheumatoid arthritis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT00251576","phase":"PHASE3","title":"Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1999-11-01","conditions":"Acute Coronary Syndrome","enrollment":4497},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT02980120","phase":"","title":"Personality Pathology and Cerebral Processing in Eating Disorders","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2015-01","conditions":"Eating Disorders","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Duration of Treatment: Z-Phase, 2 years.","genericName":"Duration of Treatment: Z-Phase, 2 years.","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Z-Phase is a medication that targets the body's natural processes to reduce inflammation and slow disease progression. Used for Moderate to severe rheumatoid arthritis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}